# OnCo record brigatinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/brigatinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "brigatinib" ;
  schema:name "Brigatinib"@en ;
  schema:description "Brigatinib is an ALK pill with strong brain activity, approved first after crizotinib and then first line after beating it in ALTA-1L."@en ;
  schema:url <https://onco.cc/drugs/brigatinib/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Brigatinib> ;
  owl:sameAs <http://www.wikidata.org/entity/Q27456393> ;
  schema:citation <https://doi.org/10.1200/JCO.2016.71.5904>, <https://doi.org/10.1056/NEJMoa1810171>, <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=brigatinib>, <https://www.nice.org.uk/guidance/ta571>, <https://www.nice.org.uk/guidance/ta670> ;
  onco:status "approved" ;
  onco:tag "gap-fill" ;
  onco:modality "Small-molecule ALK/EGFR TKI (second generation)" ;
  schema:alternateName "Alunbrig" ;
  onco:approval "US 2017: ALK-positive metastatic NSCLC after crizotinib", "US 2020: First-line ALK-positive metastatic NSCLC", "EU 2018: ALK-positive NSCLC", "England (NICE) 2019: ALK-positive advanced non-small-cell lung cancer after crizotinib", "England (NICE) 2021: ALK-positive advanced non-small-cell lung cancer not previously treated with an ALK inhibitor" ;
  onco:acceleratedApproval "US 2017-04-28: Patients with ALK-positive metastatic NSCLC that have progressed or are intolerant to crizotinib" ;
  onco:acceleratedApprovalConfirmed "US 2020-05-22: Patients with ALK-positive metastatic NSCLC that have progressed or are intolerant to crizotinib" ;
  onco:related <https://onco.cc/biomarkers/alk-fusion/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/alk-positive-nsclc/>, <https://onco.cc/cancers/lung-cancer/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/alk/> ;
  onco:companies <https://onco.cc/companies/takeda/> ;
  onco:trials <https://onco.cc/trials/alta/>, <https://onco.cc/trials/alta-1l/> .